UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019
COELIAC DISEASE

	Results for assessment
Total distributed	53
Total submitted	53
Reference	DQA1*03:01, *05:05; DQB1*03:01, *03:02
Number acceptable	46
Number unacceptable	2
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11	HLA-DQ8(3) Positive	DQB1*02, 03:02	The presence of HLA-DQ8(3) is associated with, but not diagnostic for, coeliac disease. HLA-DQ8(3) is present in about 10%of caucasians in the normal population		09/04/2019	16/04/2019	Acceptable
12	DQ2: Negative, DQ8: Positive, DQA1*05: Positive	DQ2, DQ8, DQA1*05	This genotype is associated with genetic susceptibility for coeliac disease.		10/04/2019	12/04/2019	Acceptable
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17	DQA1*05:01 DQB1*02:01 (cis) - DQ2 Negative DQA1*05:05 02:01 DBQ1*03:01 02:02 (trans) -DQ2 - Negative DQA1*03:01 DQB1*03:02 -DQ8 - Positive	DQA1*05:01 DQB1*02:01 (cis) DQA1*05:05 02:01 DBQ1*03:01 02:02 (trans) DQA1*03:01 DQB1*03:02	The major association for Coeliac disease involves the haplotype: DQA1*05:01 â€“ DQB1*02:01 (DQ2) and a minority of cases with the haplotype: DQA1*03:01 â€“ DQB1*03:02 (DQ8). (Nature Reviews Immunology 2002:2:647) This patient is POSITIVE for the DQA1*03-DQB1*03:02 (DQ8) haplotype and has a moderate genetic risk of having or developing coeliac disease		11/04/2019	12/04/2019	Acceptable
24	DQB1*03:01/04/14/19/21/66N, *03:02/19/32/37/45/66N; DQA1*03:01, *05:05/09/11	DQB1*02, DQA1*05, DQB1*03:02	The patient possesses HLA DQB1*03:02 (DQ8) allele that is associated with Coeliac Disease. Patients with this genotype have a high risk of predisposition to Coeliac Disease, however; presence of this allele alone does not confirm diagnosis. Other clinical indications are required for diagnosis.		10/04/2019	15/04/2019	Acceptable
25	DQB1*03:01, *03:02; DQA1*03:01, *05:05/09	DQ2 DQ8	This patient is DQ8 positive heterozygous which is associated with Coeliac Disease.		10/04/2019	18/04/2019	Acceptable
38	DQB1*03:01, *03:02 DQA1*03:01, *05:05	DQB1*02 and DQB1*03:02	This individual carries the DQB1*03:02 (DQ8) variant that has an association with coeliac disease (high risk).		10/04/2019	18/04/2019	Acceptable
42	DQA1*03:01 DQA1*05:05/09/11 DQB1*03:01/03:02/03:04/03:14/03:19/03:21/03:22/03:24/03:27/03:28/03:29/03:32/03:35/03:42/03:44/03:45/03:46/03:47/03:48/03:49/03:50/03:51/03:52/03:53/03:54/03:55/03:56/03:57/03:58/03:59/03:60/03:62/03:63/03:66N/03:67/03:68/03:71/03:73/03:75/03:77/03:81/03:82/03:83/03:84N/03:85/03:92/03:93/03:94/03:101/03:102/03:103/03:106/03:107/03:108/03:109/03:114/03:115/03:116/03:118N/03:119/03:120/03:122/03:125/03:127/03:129/03:131/03:134/03:140/03:143/03:144/03:146/03:147/03:150/03:154/03:157/03:158/03:159/03:160/03:161/03:164/03:165/03:167/03:169/03:171/03:173/03:174/03:175/03:178/03:182/03:185/03:188/03:189/03:190/03:191/03:193/03:196/03:197Q/03:198/03:203/03:205/03:206/03:208/03:215/03:216/03:218/03:219/03:224/03:225/03:229/03:231/03:232/03:235/03:236/03:241/03:242/03:243/03:245/03:246/03:247/03:251/03:252/03:253/03:254/03:255/03:256/03:260/03:264/03:265/03:266/03:267/03:268/03:269N/03:273/03:275/03:276N/03:277/03:281 DQB1*03:02/03:19/03:32/03:37/03:45/03:62/03:63/03:66N/03:67/03:68/03:70/03:73/03:74/03:81/03:85/03:106/03:107/03:113/03:125/03:146/03:161/03:174/03:175/03:178/03:179/03:185/03:189/03:190/03:203/03:205/03:213N/03:215/03:221/03:224/03:225/03:229/03:245/03:247/03:251/03:252/03:263/03:265/03:269N/03:273/03:277	HLA-DQ	This patient is NEGATIVE for HLA-DQ2 (but is DQA1*05 POSITIVE) and POSITIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a HIGH RISK of predisposition to Coeliac disease though other factors are likely involved.		11/04/2019	12/04/2019	Acceptable
78	Not tested				10/04/2019	0000-00-00	Not assessed
85	DQA1*05 positive DQB1*02 negative DQB1*0302 positive		This individual has one of the HLA-DQ variants associated with coeliac disease. More than 97% of coeliac disease patients carry either HLA-DQ2 or DQ8. However, these variants are also present in approximately 40% of the general population and therefore whilst possession of the variant can support a diagnosis of coeliac disease it is not per se diagnostic of the condition.		10/04/2019	23/04/2019	Acceptable
86	Coeliac disease-associated HLA alleles present: DQB1*03:02 DQA1*03:01 HLA DQ2: ABSENT HLA DQ8: PRESENT - HLA-DQ8	DQ2 and DQ8 associated DQB1* and DQA1*	HLA-DQ8, which is associated with moderate genetic susceptibility for coeliac disease (CD), has been detected in this patient. As 25-30% of the general population has one of the CD-associated HLA alleles encodin DQ2 and/or DQ8 and only 3% of these individuals develop coeliac disease, identificatio of a CD-associated HLA allele is not diagnostic of CD. The presence of DQ2 and/or DQ increases the likelihood that the patient has CD but a diagnosis must be based on clinical findings, serum antibody detection tests and/or intestinal biopsy.		10/04/2019	23/04/2019	Acceptable
87	Positive HLA-DQ8, rest negative	HLA-DQ2.2, HLA-DQ2.5, HLA-DQ8 and Iº subunit HLA-DQ2.2/DQ2.5	90-95% of Coeliac patients are HLA DQ2 or DQ8 positive (Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:13660).		10/04/2019	12/04/2019	Acceptable
109	DQA1*05: positive DQB1*02:01 /02:02: negative DQB1*03:02: positive	DQA1*05 DQB1*02:01 /02:02 DQB1*03:02	There is an HLA-associated risk for celiac disease		10/04/2019	16/04/2019	Acceptable
113	Haemolysis of the sample. No result available	DQ2 and DQ8			09/04/2019	0000-00-00	Not assessed
123	Not Tested				0000-00-00	0000-00-00	Not assessed
124	Not Tested				0000-00-00	0000-00-00	Not assessed
126	DQA*05=POS, DQB*02=NEG, DQA*02=NEG, DQA*03=POS, DQB*0302=POS	DQA*05, DQB*02, DQA*02, DQA*03, DQB*0302			10/04/2019	15/04/2019	Acceptable
127	HLA-DQ2* negative, HLA-DQ8* positive	HLA-DQA1* HLA-DQB1*			11/04/2019	16/04/2019	Acceptable
129	DQB1*02 negative, DQB1*03:02 positive, DQA1*05 positive	DQB1*02, *03:02; DQA1*05	Moderately increased risk of coeliac disease		22/04/2019	29/04/2019	Acceptable
142	HLA-DQA1*05 present HLA-DQB1*02 absent HLA-DQB1*03:02 (DQ8) present	HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*03:02 (DQ8)	PrÃ©sence de lâ€™allÃ¨le HLA-DQB1*03:02 (DQ8) et absence de lâ€™allÃ¨le HLA-DQB1*02 (DQ2). Risque modÃ©rÃ© de prÃ©disposition Ã la maladie cÃ“liaque.		11/04/2019	22/04/2019	Acceptable
150	DQB1*03:01;03:02 DQA*03:01;05:05.	DQ2 : DQB1*02:01-DQA*05:01 DQ8 : DQB1*03:02-DQA*03:01	Presence of allele DQB1*03:02,DQA*03:01.		17/04/2019	18/04/2019	Acceptable
154	HLA-DQA1*03:01,*05:05 HLA-DQB1*03:01,*03:02	HLA-DQA1*, and HLA-DQB1* are typed to the 4-digit level to determine whether HLA-DQ2 is coded by DQA1*05:01, DQB1*02:01 ; HLA-DQ2 is coded by DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 ; HLA-DQ8 is coded by DQA1*03:01, DQB1*03:02	haplotype DQA1*05:01, DQB1*02:01 : absence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01,DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : Presence The patient has a suceptibility gene to celiac disease (haplotype encoding HLA-DQ8). >95% of celiac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of celiac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of celiac disease.		10/04/2019	17/04/2019	Acceptable

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

159	DQA1*03 positive, DQA1*05 positive, DQB1*02 negative and DQB1*03:02 positive	DQA1*03, DQA1*05, DQB1*02 and DQB1*03:02	Presence of susceptibility phenotype for coeliac disease	11/04/2019	12/04/2019 Acceptable
173	DQA1*05POSITIVE DQB1*02NEGATIVE DQA1*03POSITIVE DQB1*03:02 POSITIVE DQB1*03:03 NEGATIVE	HLA-DQA1*05, HLA-DQA1*03, HLA-DQB1*02, HLA-DQB1*03:02, HLA-DQB1*03:03	DQ8 POSITIVE	17/04/2019	23/04/2019 Acceptable
176	DQA1*05-Pos DQB1*02-NEG DQB1*03:02-Pos	DQA1*05 DQB1*02 DQB1*03:02	Celiac tissue type examination: Negative for HLA-DQB1 * 02 (DQ2) and positive for HL DQB1 * 03: 02 (DQ8). The genetic risk of celiac disease is present.	15/04/2019	16/04/2019 Acceptable
201	DQA1*03:01 DQA1*05:05 DQB1*03:01 DQB1*03:02			10/04/2019	17/04/2019 Acceptable
219	DQB1*03:02 positive DQA1*05: positive DQB1*02: negative DQA1*02: negative Reported serotype: DQ8	HLA-DQB1*03:02, HLA-DQA1*05, HLA-DQB1*02, HLA-DQA1*02	English translation: "HLA-DQ8 is detected in the form of HLA-DQB1*03:02. HLA-DQB1*02 is not detected. Some coeliac patients have this allele. The allele is common in the general population. Coeliac disease is not very likely, but can not be excluded."	24/04/2019	30/04/2019 Acceptable
223	DQA1*02 negative, DQA1*03 positive, DQA1*05 positive, DQB1*02 negative, DQB1*03:02 positive	DQA1*02, DQA1*03, DQA1*05, DQB1*02, DQB1*03:02		10/04/2019	16/04/2019 Acceptable
224	DQA1*05=POS; DQB1*02=NEG; DQB1*03:02 group (DQ8)=POS			10/04/2019	17/04/2019 Acceptable
225	DQ2-negative, DQ8-positive	DQA1*02, DQA1*03, DQA1*05 DQB1*02, DQB1*03:02	The patient is DQ8-positive. Coeliac disease is associated with this HLA-type in 5%	15/04/2019	16/04/2019 Acceptable
245	DQB1*03,*03 (serological equivalents: DQ7 and DQ8); DQA1*03,*05	DQB1*02+DQA1*05 DQB1*02 DQB1*03:02	Presence of DQ8 antigen: low to very low risk to develop coeliac disease. This result alone does not confirm the diagnosis.	10/04/2019	17/04/2019 Acceptable
255	DQA1*05 pos and DQB1*0302 pos	DQA1*05, DQB1*02, DQB1*0302	DQ2.5 neg DQ8 pos	10/04/2019	23/04/2019 Acceptable
263	DQA1*0201 absent, DQA1*03 present, DQA1*05 present DQB1*02 absent, DQB1*0302 present	HLA-DQA1*0201, DQA1*03, DQA1*05 HLA-DQB1*02, DQB1*0302 Homozygous or heterozygous status for DQB1*02 only	The search for HLA-DQ8 (DQA1 *03-DQB1 *0302), which is compatible with celiac disease, was positive.	18/04/2019	23/04/2019 Acceptable
269	DQ8 positive	HLA DQ2.2 HLA DQ2.5 HLA DQ8	HLA DQ2.2 negative HLA DQ2.5 negative HLA DQ8 positive	07/04/2019	17/04/2019 Acceptable
274	HLADQ2trans HP1carrier + HLA DQ8 (detected: DQA1*05, DQB1*0301, DRB1*11, DQA1*03, DQB1*0302, DRB1*04)	HLADQ2cis, HLADQ2trans, HLA DQ2trans hp1, HLADQ2trans hp2, HLA DQ8		12/04/2019	15/04/2019 Acceptable
276	DQA1*05 positive, DQB1*02 negative; DQB1*03:02 positive	DQA1*05 DQB1*02 DQB1*03:02		10/04/2019	23/04/2019 Acceptable
278	Positive for genotype HLA-DQ8	DQA1*02, DQA1*02/*0301, DQA1*03, DQA1*0302/03, DQA1*05, DQB1*02, DQB1*02	The genotype indicates a risk of developing coeliac disease.	15/04/2019	25/04/2019 Acceptable
279	Not Tested			0000-00-00	0000-00-00 Not assessed
281	Positive association with coeliac disease. DQA1*03:01-DQB1*03:02 type.	DQA1* DQB1*		09/04/2019	16/04/2019 Acceptable
307	DQA1*03:01,*05:05 DQB1*03,*03:02	DQA1*02 DQA1*05 DQA1*03 DQB1*02 DQB1*03:02	Presence of HLA-DQ8 heterodimer (DQA1*03,DQB1*03:02).	10/04/2019	12/04/2019 Acceptable
315	POSITIVE (DQB1*03:01, DQB1*03:02)	DQB1*02, DQB1*03:02		10/04/2019	16/04/2019 Acceptable
317	Positive for allels: DQA1x03, DQA1x02/x0301, DQA1x05, DQB1x02/x0302	HLA DQA1 and HLA DQB1	Positive for HLA DQ 8	15/04/2019	17/04/2019 Unacceptable
319	DQ2 Neg DQ8 Pos	DQA1*05 Pos DQB1*02 Neg DQB1*0302 Pos		10/04/2019	12/04/2019 Acceptable
331	DQB1*03:01/03:13, DQB1*03:04	DQB1*02:01, DQB1*03:02	Absence of DQB1*02:01 ; absence of DQB1*03:02	12/04/2019	24/04/2019 Unacceptable
333	DQA1*05, DQB1*0301, DRB1*11, DQA1*03, DQB1*0302, DRB1*04	DQA1*05, DQA1*02, DGA1*03, DQB1*02, DQB1*0301, DQB1*0302, DRB1*03, DRB1*11, DRB1*12, DRB1*07, DRB1*04		15/04/2019	18/04/2019 Acceptable
338	DQB1*03:01,*03:02;DQA1*03:01,*05:05;DRB1*04,*11	HLA-DQB1; DQA1 ;DRB1*03,*04,*07,*11	Celiac Disease predisposing HLA-DQ types. The presence of the heterodimers DQ8 (DQA1*03,DQB1*03:02) is indicative of susceptibility to CD but it does not imply the development of the disease whose diagnosis must be verified by clinical method.The second haplotype DQB1*03:01, DQA1*05:05, DRB1*11 (DQ7.5) is not associated with Celiac Disease according to ESPHGAN guideline .	11/04/2019	28/05/2019 Acceptable
339	Found DQA105 positive and DQB10302 positive, therefore genotype: DQ8	DQA105, DQB102 and DQB10302		10/04/2019	16/04/2019 Acceptable
346	HLA-DQA1*05-POS, HLA-DQB1*02-NEG, HLA-DQB1*03:02P (DQ8)-POS	DQA1*05, DQB1*02, DQB1*03:02P (DQ8)		16/04/2019	23/04/2019 Acceptable
347	HLA-DQ2.5-negative, HLA-DQ2.2-negative, HLA-DQ8-positive	HLA-DQA1 / HLA-DQB1	Increased risk for the development of Coeliac Disease; determination of serological parameters or biopsy from the small intestine recommended.	16/04/2019	17/04/2019 Acceptable
355	HLA-DQ8 positive		The patient has a genetic disposition to develop celiac disease. Analyzing for celiac antibodies in plasma is recommended.	10/04/2019	30/04/2019 Acceptable
359	Alleles positive:DQA1*03, DQA1*05, DQA1*02/*03:01, DQB1*03:02, DQB1*03/*06, alfa-subunit HLA-DQ2.5, alfa-subunit HLA-DQ8, beta-subunit HLA-DQ8	DQA1*02, DQA1*03, DQA1*05, DQA1*01/*04/*06, DQA1*02/*03:01, DQA1*03:02/03, DQB1*02, DQB1*03:02, DQB1*03/*06, DQB1*04/*05, alfa-subunitHLA-DQ2.2, alfa-subunitHLA-DQ2.5, alfa-subunitHLA-DQ8, beta-subunit HLA-DQ2.2/DQ2.5, beta-subunit HLA-DQ8	HLA-DQ8: positive	11/04/2019	17/04/2019 Acceptable
363	HLA DQ2.2 = Absent ; HLA DQ2.5 = Absent ; HLA DQ8 = Present	DQA1*02; DQA1*02/*0301; DQA1*03; DQA1*0302/03; DQA1*05; DQB1*02; DQB1*02/*0302.		09/04/2019	16/04/2019 Acceptable
413	DQ8 present (DQA1*03, *05:05; DQB1*03:02, *03:01; DRB1*04, *11)	DQ2, DQ8 based on the results of DQA1*05:01; DQA1*05:05; DQA1*02:01; DQA1*03; DQB1*02:02; DQB1*02:01; DQB1*03:02; DRB1*.		10/04/2019	15/04/2019 Acceptable
1350	DQ8, DQ2 trans haplotype (Hp1) carrier	detected alleles (allelic groups): HLA-DQ2 cis (DQ2.5): DQA1*05-DQB1*02-DRB1*03 HLA-DQ2 trans (DQ2.5): DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 DQA1*02-DQB1*02-DRB1*07 HLA-DQ2 trans haplotype (Hp1) carrier: DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 HLA-DQ2 trans haplotype (Hp2) carrier (DQ2.2): DQA1*02-DQB1*02-DRB1*07 DQ8:DQA1*03-DQB1*03:02-DRB1*04	detected HLA genotype is associated with the risk of coeliac disease	10/04/2019	16/04/2019 Acceptable

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019

NARCOLEPSY	Results for assessment
Total distributed	21
Total submitted	21
Reference	DQB1*03:01, *03:02
Number acceptable	19
Number unacceptable	1
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11	DQB1*06:02 Negative	DQB1*06:02	HLA-DQB1 allele known to be associated with Narcolepsy is not present		09/04/2019	16/04/2019	Acceptable
12					10/04/2019	12/04/2019	Not assessed
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17	DQB1*06:02. Negative	DQB1*06:02	This patient is NEGATIVE for the narcolepsy associated allele DQB1*06:02		11/04/2019	12/04/2019	Acceptable
24	DQB1*03:01/04/14/19/21/66N, *03:02/19/32/37/45/66N; DQA1*03:01, *05:05/09/11	DQB1*06:02	HLA-DQB1*06:02 is associated with narcolepsy-cataplexy. This patient is NEGATIVE for HLA-DQB1*06:02.		10/04/2019	15/04/2019	Acceptable
25	DQB1*06:02 negative	DQB*06:02			10/04/2019	18/04/2019	Acceptable
38	DQB1*03:01, *03:02	DQB1*06:02	The patient does not carry the associated HLA alleles which confer susceptibility to Narcolepsy		10/04/2019	18/04/2019	Acceptable
42	DQB1*03:01/03:02/03:04/03:14/03:19/03:21/03:22/03:24/03:27/03:28/03:29/03:32/03:35/03:42/03:44/03:45/03:46/03:47/03:48/03:49/03:50/03:51/03:52/03:53/03:54/03:55/03:56/03:57/03:58/03:59/03:60/03:62/03:63/03:66N/03:67/03:68/03:71/03:73/03:75/03:77/03:81/03:82/03:83/03:84N/03:85/03:92/03:93/03:94/03:101/03:102/03:103/03:106/03:107/03:108/03:109/03:114/03:115/03:116/03:118N/03:119/03:120/03:122/03:125/03:127/03:129/03:131/03:134/03:140/03:143/03:144/03:146/03:147/03:150/03:154/03:157/03:158/03:159/03:160/03:161/03:164/03:165/03:167/03:169/03:171/03:173/03:174/03:175/03:178/03:182/03:185/03:188/03:189/03:190/03:191/03:193/03:196/03:197Q/03:198/03:203/03:205/03:206/03:208/03:215/03:216/03:218/03:219/03:224/03:225/03:229/03:231/03:232/03:235/03:236/03:241/03:242/03:243/03:245/03:246/03:247/03:251/03:252/03:253/03:254/03:255/03:256/03:260/03:264/03:265/03:266/03:267/03:268/03:269N/03:273/03:275/03:276N/03:277/03:281 DQB1*03:02/03:19/03:32/03:37/03:45/03:62/03:63/03:66N/03:67/03:68/03:70/03:73/03:74/03:81/03:85/03:106/03:107/03:113/03:125/03:146/03:161/03:174/03:175/03:178/03:179/03:185/03:189/03:190/03:203/03:205/03:213N/03:215/03:221/03:224/03:225/03:229/03:245/03:247/03:251/03:252/03:263/03:265/03:269N/03:273/03:277	HLA-DQB1*06:02	This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.		11/04/2019	12/04/2019	Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109	DQA1*01:02: negative DQB1*06:02: negative	DQA1*01:02 DQB1*06:02	There is no HLA-associated risk for narcolepsy disease		10/04/2019	16/04/2019	Acceptable
113	Haemolysis of the sample. No result available	DQB1*06:02			09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127	HLA-DQB1*06:02 negative	HLA-DQB1*06:02			11/04/2019	16/04/2019	Acceptable
129	DQB1*06:02 negative	DQB1*06:02	Risk of narcolepsy not increased		22/04/2019	29/04/2019	Acceptable
142	HLA-DQB1*06:02 absent	HLA-DQB1*06:02			11/04/2019	22/04/2019	Acceptable
150	DQB1*03:01;03:02.	DQB1*06:02.	Absence of allele DQB1*06:02.		17/04/2019	18/04/2019	Acceptable
154	HLA-DQB1*03:01,*03:02	HLA-DQB1*06:02	Allele DQB1*06:02 : absence The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.		10/04/2019	17/04/2019	Acceptable
159	DQB1*06:02 negative, DQA1*01:02 negative	DQB1*06:02, DQA1*01:02	Absence of susceptibility phenotype for narcolepsy		11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223	DQA1*01:02 negative, DQB1*06:02 negative	DQA1*01:02, DQB1*06:02			10/04/2019	16/04/2019	Acceptable
224	DQA1*01:02=NEG; DQB1*06:02=NEG				10/04/2019	17/04/2019	Acceptable
225	DQB1*06:02-negaive	DQB1*06:02	The patient donÂ´t have the HLA-type thatÂ´s associated with narcolepsy,		15/04/2019	16/04/2019	Acceptable
245	DQB1*03,*03 (serological equivalents: DQ7 and DQ8)	DQB1*06:02	Absence of the susceptibility allele for narcolepsy-cataplexy DQB1*06:02. This allele is present in 12 to 38% of the general population, in 40 to 60% of patients with narcolepsy without cataplexy and in 18% of patients with idiopathic hypersomnia. This result makes the diagnosis of narcolepsy-cataplexy unlikely but does not exclude the diagnosis.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276	DQB1*06:02 negative	DQB1*06:02			10/04/2019	23/04/2019	Acceptable
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281	No known association with narcolepsia.	DQB1*			09/04/2019	16/04/2019	Acceptable
307					10/04/2019	12/04/2019	Not assessed
315	NEGATIVE (DQB1*03:01, DQB1*03:02)	DQB1*06:02			10/04/2019	16/04/2019	Acceptable
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DQB1*03:01/03:13, DQB1*03:04	DQB*06:02	Absence of DQB1*06:02		12/04/2019	24/04/2019	Unacceptable
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019

ACTINIC PRURIGO	Results for assessment
Total distributed	3
Total submitted	3
Reference	DRB1*11:01, *04:04
Number acceptable	3
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	DRB1*04:07 negative	DRB1*04:07	This patient is Negative for the HLA DRB1*04:07 allele associated most strongly with Actinic Prurigo but is Positive for HLA DRB1*04		10/04/2019	18/04/2019	Acceptable
38	DRB1*11:01, *04:04	DRB1*04:07	This patient does not carry DRB1*04:07, which confers susceptibility to Actinic Prurigo		10/04/2019	18/04/2019	Acceptable
42	DRB1*04:04/04:08/04:19/04:23/04:44/04:56/04:68/04:70/04:118/04:120N/04:121/04:149/04:157N/04:177/04:193/04:205/04:220/04:221/04:223/04:224/04:231/04:247N/04:252/11:22 DRB1*11:01/11:04/11:24/11:27/11:29/11:39/11:43/11:44/11:49/11:60/11:61/11:66/11:75/11:77/11:78/11:81/11:84/11:90/11:97/11:99/11:100/11:102/11:106/11:108/11:109/11:112/11:114/11:117/11:121/11:133/11:137/11:140/11:141/11:146/11:147/11:152/11:154/11:155/11:157/11:158/11:160/11:162/11:163/11:165/11:166/11:169N/11:175/11:177/11:180/11:181/11:187/11:188/11:195/11:196/11:197/11:198/11:204/11:205/11:206/11:207/11:208/11:210/11:211/11:212/11:214/11:215/11:217N/11:219/11:220/11:221/11:222/11:223/11:224/11:225/11:227/11:228/14:183	HLA-DRB1*04:07	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07		11/04/2019	12/04/2019	Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113					09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245	Not Tested	NT	NT		10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019
BIRDSHOT RETINOPATHY

	Results for assessment
Total distributed	7
Total submitted	7
Reference	A*24, *29
Number acceptable	7
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11	HLA-A29 Positive	A*29	HLA-A allele known to be associated with but not diagnostic for birdshot chorioretinopathy is present		09/04/2019	16/04/2019	Acceptable
12					10/04/2019	12/04/2019	Not assessed
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	A*29 positive	A*29	The HLA A29 antigen associated with Birdshot Chorioretinopathy is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.		10/04/2019	18/04/2019	Acceptable
38	A*24, *29	A*29	This patient carries HLA-A*29 which confers susceptibility to Birdshot Retinopathy		10/04/2019	18/04/2019	Acceptable
42	A*24:02/24:02L/24:02Q/24:03/24:07/24:09N/24:11N/24:13/24:20/24:25/24:27/24:33/24:35/24:36N/24:37/24:38/24:39/24:40N/24:43/24:45N/24:47/24:49/24:57/24:58/24:68/24:69/24:70/24:74/24:76/24:78/24:79/24:80/24:82/24:83N/24:84N/24:86N/24:88/24:95/24:98/24:99/24:101/24:102/24:104/24:108/24:111/24:116/24:117/24:119/24:120/24:122/24:123/24:125/24:126/24:127/24:128/24:131/24:132N/24:134/24:135/24:137/24:139/24:140/24:141/24:142/24:144/24:147/24:148/24:149/24:150/24:151/24:152/24:153/24:154/24:155N/24:159/24:161/24:162/24:163N/24:165/24:166/24:169/24:170/24:171/24:172/24:173/24:175/24:176/24:178/24:179/24:180/24:181/24:183N/24:185N/24:192/24:193/24:195/24:196/24:197/24:198/24:202/24:205/24:206/24:209/24:212/24:215/24:216/24:217/24:218/24:220/24:221/24:223/24:224/24:225/24:226/24:231/24:232N/24:234/24:235/24:236/24:238/24:239/24:242/24:244/24:245/24:246/24:247/24:248/24:249/24:250/24:251/24:252N/24:253/24:254/24:257/24:258/24:259/24:260/24:261/24:263/24:264/24:265/24:266/24:267/24:268/24:269/24:270/24:271/24:272/24:274/24:275/24:276/24:278N/24:279/24:280/24:281/24:282/24:284/24:286/24:287/24:288/24:292/24:295/24:297/24:298/24:303N/24:305/24:311/24:312N/24:313/24:317/24:320/24:321/24:322/24:323N/24:328/24:332/24:334/24:336/24:337/24:338/24:341/24:343/24:345/24:346/24:347/24:348/24:350/24:352/24:353/24:354/24:356/24:358/24:359N/24:360/24:362/24:363/24:364/24:365/24:366/24:368/24:369/24:371/24:377/24:380/24:382/24:383/24:384/24:385/24:386/24:388N/24:389N/24:391/24:393/24:396N/24:397/24:398/24:400/24:401/24:402/24:403 A*29:02/29:03/29:06/29:07/29:10/29:11/29:21/29:23/29:26/29:27/29:29/29:30/29:34/29:36/29:37/29:42/29:43/29:44/29:46/29:49/29:50/29:52/29:53/29:54/29:59/29:63/29:65/29:66/29:68/29:70/29:72/29:75/29:78N/29:87/29:88/29:91/29:94/29:95/29:96/29:100/29:102/29:103/29:106/29:108/29:111/29:112N	HLA-A*29	This patient is HLA-A*29 POSITIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.		11/04/2019	12/04/2019	Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113					09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150	A*24;29	A*29	Prence of allele A*29		17/04/2019	18/04/2019	Acceptable
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245	A*24,*29	A*29	Presence of the A*29 susceptibility allele. The presence of the A*29 allele, associated with the clinical signs of the disease, is strongly in favor of the diagnosis of birdshot disease. The prevalence of A*29 in patients with birdshot is 90 to 100% according to published studies.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315	POSITIVE (A*24, A*29)	A*29			10/04/2019	16/04/2019	Acceptable
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019

BEHCET'S DISEASE	Results for assessment
Total distributed	12
Total submitted	12
Reference	B*40, *44
Number acceptable	10
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11	HLA-B51(5) Negative	B*51	The HLA allele associated with Behcet's disease is absent		09/04/2019	16/04/2019	Acceptable
12	HLA B*51: Negative	HLA B*51	This patient is negative for HLA-B*51 (the HLA specificity associated with Behcet's disease). Note: HLA-B*51 alleles with a population frequency <0.001% (identified on http://www.allelefrequencies.net) may not be detected by this assay.		10/04/2019	12/04/2019	Acceptable
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	B*51 negative	B*51	Patient is Negative for the B51 antigen which is associated with Bechets Disease.		10/04/2019	18/04/2019	Acceptable
38	HLA-B*40, *44	B*51	This patient does not carry HLA-B*51, which confers susceptibility to Behcet's disease.		10/04/2019	18/04/2019	Acceptable
42	B*40:02/40:29/40:35/40:56/40:57/40:78/40:82/40:90/40:91/40:97/40:104/40:107/40:111/40:115/40:122/40:142N/40:144N/40:145/40:157/40:164/40:169/40:176/40:181/40:189/40:200/40:202/40:206/40:211/40:214/40:219/40:224/40:226/40:255/40:266/40:271/40:274/40:283/40:287/40:290/40:291N/40:293/40:296/40:297/40:302/40:303/40:304/40:320/40:331/40:334/40:345N/40:356/40:359/40:369/40:371 B*44:03/44:13/44:26/44:32/44:35/44:36/44:38/44:39/44:46/44:61N/44:69/44:81/44:85/44:89/44:92/44:94/44:98/44:103/44:108N/44:111/44:114/44:115/44:120/44:122/44:125/44:128/44:129/44:141/44:147/44:155/44:157/44:159/44:161/44:164/44:165/44:167/44:174/44:178/44:182/44:183/44:186/44:188/44:189/44:192/44:198N/44:202/44:205/44:207/44:222/44:228/44:231/44:233/44:237N/44:239/44:250/44:252/44:258/44:272/44:278/44:280/44:281/44:283/44:284/44:286	HLA-B*51	This patient is HLA-B*51 NEGATIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.		11/04/2019	12/04/2019	Acceptable
78	Not tested				10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	B51			09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142	HLA-B*51 absent	HLA-B*51			11/04/2019	22/04/2019	Acceptable
150	B*40;44.	B*51	Absence of allele B*51.		17/04/2019	18/04/2019	Acceptable
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173	HLA-B*51 NEGATIVE	HLA-B*51	Low risk of BehÃ§et Syndrome		17/04/2019	23/04/2019	Acceptable
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245	B*40,*44 (B*40 serological equivalent: B61)	B*51	Absence of the susceptibility allele HLA-B*51. This result does not exclude the diagnosis of BehÃ§et's disease: 30-50% of patients do not have the B*51 allele.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315	NEGATIVE (B*40, B*44)	B*51			10/04/2019	16/04/2019	Acceptable
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019

RHEUMATOID ARTHRITIS

	Results for assessment
Total distributed	2
Total submitted	2
Reference	DRB1*11:01, *04:04
Number acceptable	1
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	DRB1*04/DQA1*03:01/DQB1*03:02, DRB1*03:01/DQA1*05:01/DQB1*02:01			09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245	DRB1*04,*11	DRB1*04:01,*04:04,*04:05,*04:08 DRB1*10 DRB1*01:01,*01:02,*01:04 DRB1*14:06	Detection of shared epitope, single dose. This result favors rheumatoid arthritis only if it is associated with the clinical, biological and/or radiological signs corresponding to the diagnostic criteria (ACR 2010) (OR = 3.5-6.8 for a single dose; OR = 11.4-33.3 for a double dose).		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DRB1*04, DRB1*11	DRB1*04	Presence of DRB1*04		12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019	
DIABETES	Results for assessment
Total distributed	5
Total submitted	5
Reference	DRB1*11:01, *04:04; DQA1*03:01, *05:05; DQB1*03:01, *03:02
Number acceptable	4
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	DRB1*04/DQA1*03:01/DQB1*03:02, DRB1*03:01/DQA1*05:01/DQB1*02:01			09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129	DQB1*03:01, *03:02; DQA1*03, *05; DRB1*04:04 present	DQB1'02, *03:01, *03:02, *03:03, *03:04,*04, *05, *06:01,*06:02, *06:03, *06:04; DQA1*02:01, *03, *05; DRB1*04:01, *04:02, *04:03/6, *04:05, *04:07	Neutral genotype, combination of risk and protection associated haplotypes		22/04/2019	29/04/2019	Acceptable
142					11/04/2019	22/04/2019	Not assessed
150	DRB1*04:04;11:01.	DR3 : DRB1*03:01 DR4 : DRB1*04:05	Presence of allele DR4 but absence of allele DRB1*04:05.		17/04/2019	18/04/2019	Acceptable
154	HLA-DRB1*04,*11; HLA-DQA1*03:01,*05:05; HLA-DQB1*03:01,*03:02	HLA-DRB1* is typed to the 2-digit level and HLA-DQA1* and HLA-DQB1* are typed to the 4-digit level to detect the following haplotypes : HLA-DRB1*03, DQA1*05:01, DQB1*02:01 and HLA-DRB1*04, DQA1*03:01, DQB1*03:02	haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : absence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : Presence The patient expresses the HLA-DR4,DQ8 haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.		10/04/2019	17/04/2019	Acceptable
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245	DRB1*04,*11; DQA1*03,*05; DQB1*03,*03 (serological equivalents: DQ7 and DQ8)	Susceptible: DRB1*03:01;DQA1*05:01;DQB1*02:01 DRB1*04:01;DQA1*03:01;DQB1*03:02/04 DRB1*04:02;DQA1*03:01;DQB1*03:02/04 DRB1*04:04;DQA1*03:01;DQB1*03:02/04 DRB1*04:05;DQA1*03:01;DQB1*03:02/04 Protector: DRB1*15:01;DQA1*01:02;DQB1*06:02 DRB1*14:01;DQA1*01:01;DQB1*05:03 DRB1*07:01;DQA1*02:01;DQB1*03:03 DRB1*04:03;DQA1*03:01;DQB1*03:02	Presence of alleles that may constitute a susceptibility haplotype HLA-DRB1*04:04/DQA1*03:01/DQB1*03:02, giving the individual carrier an increased risk c developing type I diabetes, with an odds ratio of 1.59. This result is not a diagnostic criterion for the disease.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DRB1*04, DRB1*11	DRB1*03, DRB1*04	Absence of DRB1*03 ; Presence of DRB1*04		12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

802/2019

OTHER	Results for assessment
Total distributed	0
Total submitted	0
Reference	
Number acceptable	-
Number unacceptable	-
Assessed ☑	☑

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113					09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	16/04/2019	Not assessed
245					10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed